Hemay has always been committed to the mission of "developing more effective, safer and more economical new drugs for patients", adhering to the attitude of "being responsible for patients". Through teamwork and scientific innovation, it is actively building a world-class value drug research and development and production base. The company's research and development does not blindly pursue new targets and hot tracks. It insists on taking its own research and development platform and core technology as the basis, and focuses on creating products with outstanding clinical value. The company's research and development pipeline covers areas such as autoimmune diseases and tumors. So far, it has successfully completed the screening of dozens of new compounds, among which 12 indications of 5 first-class innovative drugs are undergoing clinical trials, and several indications are in the key clinical trial stage. The projects have been recognized and supported by various departments and research institutions on multiple occasions, and have independently undertaken 3 national "Major New Drug Creation" science and technology major special projects.
| No. | Project | Target Population | Trial Title |
|---|---|---|---|
| 1 | Mufemilast |
Behcet's Disease (BD) Patients |
A multicenter, randomized, double-blind, placebo-controlled |
| 2 | Mufemilast |
Patients with Moderate-to-Severe Atopic Dermatitis (AD) |
A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of Mufemilast tablets in the treatment of moderate-to-severe atopic dermatitis. (Drug Clinical Trial Registration and Information Public Platform) |
| 3 | Mufemilast |
Patients with Moderate-to-Severe Active Ankylosing Spondylitis (AS) |
A multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of Mufemilast tablets in the treatment of active ankylosing spondylitis. (Drug Clinical Trial Registration and Information Public Platform) |
| 4 | Mufemilast |
Patients with Moderate-to-Severe Ulcerative Colitis (UC) |
A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of Mufemilast in patients with moderate-to-severe ulcerative colitis. (Drug Clinical Trial Registration and Information Public Platform) |
| 5 | Hemay022 |
Patients with Moderate-to-Severe Atopic Dermatitis (AD) |
A randomized, open-label, controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of Hemay022 in combination with aromatase inhibitors in postmenopausal patients withHER2+/ER+ advanced breast cancer previously treated with a trastuzumab-containing regimen. (Drug Clinical Trial Registration and Information Public Platform) |
| 6 | Hemay181 |
Patients with Advanced Solid Tumors |
A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of Hemay181 in patients with advanced solid tumors. (Drug Clinical Trial Registration and Information Public Platform) |
| 7 | Hemay808 |
Patients with mild to moderate atopic dermatitis |
A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of Hemay181 in patients with advanced solid tumors. (Drug Clinical Trial Registration and Information Public Platform) |
Adverse Drug Event Reporting and Medical Inquiry
Adverse Drug Event Reporting: 022-24929199
Phone number pending(Monday-Friday 9:00-12:00; 13:30-17:30)
Medical Inquiry: 022-24929530
Patient Recruitment Inquiry: 022-24899570
